地舒单抗在骨质疏松症临床合理用药的中国专家建议

Chinese expert recommendations on the clinical rational use of denosumab in osteoporosis

骨质疏松症已成为我国重要的公共健康问题。地舒单抗作为一种具有较广抗骨折谱的抗骨质疏松药物,在国外应用已超过10年,大量的临床证据显示其可持续增加绝经后骨质疏松症的骨密度,并降低椎体、非椎体及髋部骨折的风险。地舒单抗在国内上市为骨质疏松症的治疗提供了一种新“武器”,但我国临床工作者对地舒单抗的应用经验尚不多。为此,中华医学会骨质疏松和骨矿盐疾病分会组织专家,在充分复习汇总循证医学证据的基础上,对地舒单抗在骨质疏松症中的临床合理用药提出建议,以供参考。

Osteoporosis has become a significant public health problem in China.Denosumab has been used abroad for more than 10 years as an anti-osteoporosis drug with a broad spectrum of anti-fracture efficacy.Abundant clinical evidence has demonstrated that denosumab can consistently increase bone mineral density in postmenopausal women with osteoporosis and reduce the risk of vertebral,nonvertebral,and hip fractures.Denosumab has recently been approved for the treatment of postmenopausal osteoporosis in China.However,practitioners in China have little experience in the clinical application of denosumab.Therefore,after a comprehensive review of relevant evidence,experts organized by the Chinese Society of Osteoporosis and Bone Mineral Research proposed recommendations on the clinical rational use of denosumab in osteoporosis.